August 16, 2025 — Late yesterday FDA granted Wegovy (semaglutide 2.4 mg) a big new indication – treatment of MASH. The indication FDA approved reads as follows: “For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. “The indication […]
July 1, 2025 — A dramatic race is progressing quietly and out of view for most of us. It is the race toward better therapy for the liver disease doctors know as MASH (metabolic associated steatohepatitis), which has close ties to obesity. And likewise because of advances in obesity science, progress in treating MASH is advancing with blinding speed […]
May 1, 2025 — Late yesterday, the New England Journal of Medicine published interim results from a study that points to another breakthrough for semaglutide – this time for a MASH indication. The analysis includes 800 patients with MASH with an average BMI of 34.5. Only 22 patients in this trial had a BMI that indicated leanness. Nearly two […]
January 27, 2025 — A new paper this morning in Nature Medicine tells us that interrupting liver disease in obesity is possible with metabolic surgery. More specifically, in an observational study of patients with obesity and cirrhosis due to MASH, Ali Aminian and colleagues found a 72% lower risk of major complications from liver disease in patients who received […]
October 30, 2024 — November is upon us and thus, so is ObesityWeek 2024 in San Antonio. This has been a year of radical change in the environment for obesity research, prevention, and care. So as we peruse the program for this meeting, it comes across as a year for consolidating the understanding of this disease and transformative options […]
July 23, 2024 — Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Formerly known as nonalcoholic fatty liver disease, this condition affects 1 in 4 people worldwide. Among those with type 2 diabetes, insulin resistance, obesity, or all three, […]
June 25, 2024 — It’s over. The 84th Scientific Sessions of the American Diabetes Association came to an end yesterday and for anyone interested in obesity, it has given us a lot to absorb. After four days with a steady stream of new information about drugs like the GLP-1 agonists that regulate appetite and adiposity, we are left wondering. […]
June 9, 2024 — At the EASL Congress 2024 in Milan, we witnessed quite a splash of new data on both survodutide and tirzepatide for MASH. Friday and Saturday gave us two headline presentations at the meeting and two publications in the New England Journal of Medicine. Lilly pronounced itself “very pleased” with the results of their SYNERGY-NASH study […]
June 6, 2024 — On the opening day of the EASL Congress in Milan, we got a peek at more details on the results of the phase 2 study of tirzepatide in MASH (metabolic dysfunction associated steatohepatitis). The study, called SYNERGY-NASH, will be the subject of a late-breaking presentation on Saturday at the meeting. But the release of the […]
May 9, 2024 — We’re packing our bags for Venice, where the European Congress on Obesity (ECO 2024) will start in just a few days. A lot will be coming at us in a short space of time, so taking time to set some priorities is essential. Thus, we have a short list of things that we’ll be seeking […]
